|
市場調査レポート
商品コード
1379167
アジア太平洋地域の細胞・遺伝子治療バイオマニュファクチャリング市場:2022-2031年Asia-Pacific Cell and Gene Therapy Biomanufacturing Market - Analysis and Forecast, 2022-2031 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
アジア太平洋地域の細胞・遺伝子治療バイオマニュファクチャリング市場:2022-2031年 |
出版日: 2023年11月10日
発行: BIS Research
ページ情報: 英文 108 Pages
納期: 2~3営業日
|
アジア太平洋地域の細胞・遺伝子治療バイオマニュファクチャリングの市場規模は、2022年の19億6,000万米ドルから、予測期間中は17.88%のCAGRで推移し、2031年には86億米ドルの規模に成長すると予測されています。
同市場は、認可済みの治療法の増加やインフラ要件の高まりなどから、成長が見込まれています。また、遺伝子・細胞治療の適応症の拡大から、広範なバイオマニュファクチャリング能力も求められています。
アジア太平洋地域の細胞・遺伝子治療バイオマニュファクチャリング業界は、急速な拡大と変化の時期を迎えようとしています。この地域は、認可済み医薬品の増加やインフラ要件の高まりから、最先端のバイオマニュファクチャリングの中心地になろうとしています。同地域での大規模バイオマニュファクチャリング施設に対する大きなニーズは、遺伝子・細胞治療の対象適応症の拡大によってもたらされています。市場は、政府、製薬企業、学術機関による継続的投資によっても成長しており、新しい生命を救う薬物療法の開発に役立っています。
当レポートでは、アジア太平洋地域の細胞・遺伝子治療バイオマニュファクチャリングの市場を調査し、市場概要、市場成長への各種影響因子の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業の分析などをまとめています。
主要市場統計 | |
---|---|
予測期間 | 2022-2031年 |
2022年評価 | 19億6,000万米ドル |
2031年予測 | 86億米ドル |
CAGR | 17.88% |
|
“The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Expected to Reach $8.60 Billion by 2031.”
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2022 - 2031 |
2022 Evaluation | $1.96 Billion |
2031 Forecast | $8.60 Billion |
CAGR | 17.88% |
The Asia Pacific (APAC) Cell and Gene Therapy Biomanufacturing Market is expected to grow at a CAGR of 17.88% from $1.96 Billion in 2022 to $8.60 Billion in 2031 in the forecasted period of 2022-2031. APAC cell and gene therapy biomanufacturing industry is expected to grow due in part to the increasing number of authorized treatments and growing infrastructural requirements. Extensive biomanufacturing capabilities are also required due to the expanding target indications for gene and cell treatments.
The industry for cell and gene therapy biomanufacturing in Asia-Pacific (APAC) is about to undergo a period of rapid expansion and change. This area is set to become a center for state-of-the-art biomanufacturing due to the rise of authorized medicines and the rising requirements for infrastructure. A significant need for large-scale biomanufacturing facilities in Asia-Pacific is being driven by the broadening range of target indications for gene and cell therapies. The APAC market for cell and gene therapy biomanufacturing is growing as a result of continued investment in this area by governments, pharmaceutical corporations, and academic organizations, which is helping to develop novel and perhaps life-saving medical therapies. In addition to seeing the creation of cutting-edge treatments, this area is essential to the world's biomanufacturing industry.
The following are the drivers for the Asia-Pacific Cell and Gene Therapy Biomanufacturing Market:
The market is expected to face some limitations as well due to the following challenges:
Workflow/Innovation Strategy: The APAC cell and gene therapy biomanufacturing market (by product type) has been segmented into consumables, equipment, and software solutions.
Growth/Marketing Strategy: Cell and gene therapy biomanufacturing is being used for upstream processing, harvesting, downstream processing, and other applications. Various companies are providing consumables and equipment aid in the manufacturing of various cell and gene therapies, which is also the key strategy for market players to excel in the current cell and gene therapy biomanufacturing market.
Competitive Strategy: Key players in the APAC cell and gene therapy biomanufacturing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy biomanufacturing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.
|